Nikolaos Papadantonakis

Nikolaos Papadantonakis

Hematology Oncology
1365 Clifton Road Northeast
BldgC
Atlanta, GA 30322

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity.

Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity.

Journal: bioRxiv : the preprint server for biology
Published: November 28, 2024

Trans-differentiation of plasma cell neoplasm to acute myeloid leukemia with monocytic features: Case report of divergent phenotype with identical genotype.

Trans-differentiation of plasma cell neoplasm to acute myeloid leukemia with monocytic features: Case report of divergent phenotype with identical genotype.

Journal: Leukemia research reports
Published: November 19, 2024

Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities.

Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities.

Journal: Journal of personalized medicine
Published: November 05, 2024

Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity.

Identification and characterization of vasoactive intestinal peptide receptor antagonists with high-affinity and potent anti-leukemia activity.

Journal: The Journal of biological chemistry
Published: October 28, 2024

Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.

Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.

Journal: Cancers
Published: February 17, 2024

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.

Journal: Cancers
Published: December 30, 2023

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.

Journal: The Lancet. Oncology
Published: October 06, 2023

Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.

Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.

Journal: Laboratory medicine
Published: August 12, 2022

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.

A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.

Journal: Haematologica
Published: April 27, 2022

AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker.

AKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker.

Journal: Scientific reports
Published: October 22, 2021

Acute Myeloid Leukemia Case Harboring Unusual FLT3 Variant: Somatic vs Germline?

Acute Myeloid Leukemia Case Harboring Unusual FLT3 Variant: Somatic vs Germline?

Journal: Laboratory medicine
Published: December 07, 2020

Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts.

Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts.

Journal: Therapeutic advances in hematology
Published: December 20, 2019
Showing 1-12 of 28

Last Updated: 09/26/2026